Results and advantages

Since 1993, when it was first used to treat humans, Ablatherm HIFU has been included in several scientific publications outlining the results of clinical studies conducted in Europe. These studies have shown the effectiveness of this technique and the distinct benefit that it causes few of the potential side effects of other treatments. Thus, if you have been diagnosed with prostate cancer at the localised stage and if you think you meet the criteria in the "Ablatherm and you" section, you should ask your doctor about treatment with Ablatherm HIFU.

Unlike radiotherapy, the results of which are only known two years after treatment, Ablatherm HIFU enables patients to get a clearer idea of their situation soon after being treated. A few weeks after treatment, laboratory tests or a biopsy would be carried out to provide an initial indication of the effectiveness of treatment. This way, patients can consider a second course of treatment if the first session did not provide the desired results. This is a major advantage over other techniques which, if they fail, leave the patient at a therapeutic impasse because follow-up treatment is very difficult, if not impossible. In addition, Ablatherm HIFU provides non-invasive treatment, which requires only a short period of hospitalisation and allows patients to return to their everyday lives shortly thereafter.